A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT04761627
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
494
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
Ustekinumab
DRUG:
ABP 654
Sponsor
Amgen